VR Logo

Repare Therapeutics Inc. (RPTX) download report


Healthcare | Biotechnology & Pharma Research

Repare Therapeutics Inc. (RPTX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States.

IPO Date: 19-Jun-2020

Pres, CEO & Director: Mr. Lloyd Mitchell Segal

Exec. VP & CFO: Mr. Steve Forte

Listing: NASDAQ: RPTX

Country: Canada

Headquarters: Montreal, QC

Website: https://www.reparerx.com

Key Facts

Market cap: $575.21 Mln

Revenue (TTM): $7.84 Mln

Earnings (TTM): $-120.25 Mln

Cash: $311.66 Mln

Total Debt: $0.00 Mln

Insider's Holding: 11.36%

Liquidity: Low

52 Week range: $8.07 - 35.75

Shares outstanding: 41,894,200

5 Years Aggregate:

  • CFO: $-128.93 Mln
  • EBITDA: $-205.43 Mln
  • Net Profit: $-209.62 Mln

Stock Performance

Time Period Repare Therapeutics (RPTX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-35.47-8.99-19.22
1 month52.41-3.40-9.34
3 months4.77-8.50-14.58
1 Year-59.820.89-17.64
3 Years--10.415.91
5 Years--11.435.64
10 Years--11.7710.10
As on 29-Jun-2022 *As on 30-Jun-2022
Year Repare Therapeutics (RPTX) S&P Small-Cap 600 S&P BSE Sensex
2021-38.5125.2721.99